About
Technology
Issues
FAQ
Search
Scientometrics
Impact Factor
Discipline Ranks
h
-index
g
-index
Articles
Citations
Article Citations
Citation Distribution
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
Citing Bodies
Top Citing Authors
Top Citing Institutions
Top Citing Schools
Top Citing Journals
Top Citing Disciplines
exaly
›
Journals
›
Atherosclerosis Supplements
›
top-articles
Atherosclerosis Supplements
1.2
(top 50%)
impact factor
3.9K
(top 5%)
papers
14.9K
(top 20%)
citations
54
(top 10%)
h
-index
1.2
(top 50%)
impact factor
13.6K
all documents
15.8K
doc citations
94
(top 10%)
g
-index
Top Articles
#
Title
Journal
Year
Citations
1
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
Atherosclerosis Supplements
2004
1,636
2
ADMA and oxidative stress
Atherosclerosis Supplements
2003
360
3
Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase
Atherosclerosis Supplements
2002
274
4
The DDAH/ADMA/NOS pathway
Atherosclerosis Supplements
2003
259
5
NO and angiogenesis
Atherosclerosis Supplements
2003
229
6
Adiponectin: Identification, physiology and clinical relevance in metabolic and vascular disease
Atherosclerosis Supplements
2005
198
7
Familial hypercholesterolaemia: A model of care for Australasia
Atherosclerosis Supplements
2011
181
8
Trans fatty acids – Effects on systemic inflammation and endothelial function
Atherosclerosis Supplements
2006
171
9
CVD risk factors and ethnicity—A homogeneous relationship?
Atherosclerosis Supplements
2006
169
10
Diabetic dyslipidemia
Atherosclerosis Supplements
2002
166
11
Cilostazol: Potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding
Atherosclerosis Supplements
2005
157
12
Statin inhibition of HMG-CoA reductase: a 3-dimensional view
Atherosclerosis Supplements
2003
154
13
The effect of the regulation on trans fatty acid content in Danish food
Atherosclerosis Supplements
2006
141
14
Paraoxonase and coronary heart disease
Atherosclerosis Supplements
2002
133
15
Long-term effect of high dose omega-3 fatty acid supplementation for secondary prevention of cardiovascular outcomes: A meta-analysis of randomized, double blind, placebo controlled trials
Atherosclerosis Supplements
2013
131
16
Markers of inflammation and their clinical significance
Atherosclerosis Supplements
2005
125
17
Comparative pharmacology of rosuvastatin
Atherosclerosis Supplements
2003
120
18
World-wide consumption of trans fatty acids
Atherosclerosis Supplements
2006
116
19
A trans world journey
Atherosclerosis Supplements
2006
110
20
Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency
Atherosclerosis Supplements
2010
110
21
Statins: Potential new indications in inflammatory conditions
Atherosclerosis Supplements
2006
107
22
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Atherosclerosis Supplements
2004
106
23
Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography
Atherosclerosis Supplements
2013
102
24
Hugh Sinclair Lecture: The regulation and remodelling of HDL by plasma factors
Atherosclerosis Supplements
2002
100
25
ADMA: a novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease
Atherosclerosis Supplements
2003
95
26
Hyperhomocysteinemia, endothelial dysfunction, and cardiovascular risk: the potential role of ADMA
Atherosclerosis Supplements
2003
95
27
Diagnostic algorithm for familial chylomicronemia syndrome
Atherosclerosis Supplements
2017
94
28
Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration
Atherosclerosis Supplements
2016
90
29
Statins are diabetogenic – Myth or reality?
Atherosclerosis Supplements
2012
88
30
Trans fatty acids and cardiovascular disease—epidemiological data
Atherosclerosis Supplements
2006
87
31
HDL-C: Role as a risk modifier
Atherosclerosis Supplements
2011
87
32
The mechanism of the formation and secretion of chylomicrons
Atherosclerosis Supplements
2010
84
33
Novel aspects of postprandial lipemia in relation to atherosclerosis
Atherosclerosis Supplements
2008
83
34
The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practice
Atherosclerosis Supplements
2014
83
35
A nutraceutical approach (Armolipid Plus) to reduce total and LDL cholesterol in individuals with mild to moderate dyslipidemia: Review of the clinical evidence
Atherosclerosis Supplements
2017
83
36
The origin of the statins
Atherosclerosis Supplements
2004
82
37
Trans fatty intakes during pregnancy, infancy and early childhood
Atherosclerosis Supplements
2006
82
38
Asymmetric dimethylarginine (ADMA): a key regulator of nitric oxide synthase
Atherosclerosis Supplements
2003
79
39
Postprandial dyslipidemia in insulin resistance: Mechanisms and role of intestinal insulin sensitivity
Atherosclerosis Supplements
2008
77
40
The discovery and development of HMG-CoA reductase inhibitors
Atherosclerosis Supplements
2004
76
41
Pharmacological interactions of statins
Atherosclerosis Supplements
2002
72
42
Endothelial function in the post-prandial state
Atherosclerosis Supplements
2002
70
43
A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate–statin combination therapy
Atherosclerosis Supplements
2015
66
44
Is insulin resistance atherogenic? Possible mechanisms
Atherosclerosis Supplements
2006
65
45
Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study
Atherosclerosis Supplements
2017
65
46
Lipoprotein apheresis: State of the art and novelties
Atherosclerosis Supplements
2013
64
47
Do pregnancy complications and CVD share common antecedents?
Atherosclerosis Supplements
2004
63
48
Type-2 diabetes mellitus related cardiovascular risk: New options for interventions to reduce risk and treatment goals
Atherosclerosis Supplements
2006
63
49
Reduction in intestinal cholesterol absorption by various food components: Mechanisms and implications
Atherosclerosis Supplements
2010
63
50
Cilostazol in secondary prevention of stroke: Impact of the Cilostazol Stroke Prevention Study
Atherosclerosis Supplements
2005
62
site/software ©
exaly
; All materials licenced under
CC by-SA
.